Condition: Pancreas Cancer · Oligometastatic · Sponsor: M.D. Anderson Cancer Center
The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).
This description comes directly from the study's public registry record.
Ethan Ludmir, MD · (713) 825-3169 · ebludmir@mdanderson.org
Always discuss trial participation with your own doctor first.
| Cooper Hospital University Medical Center | Camden, New Jersey, United States | Recruiting |
| Cooper Hospital University Medical Center | Voorhees Township, New Jersey, United States | Recruiting |
| University of Texas Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06593431